Monthly Archives: December 2015

uPA and PAI-1 Breast Cancer Biomarkers and Clinical Utility: When Strong Evidence is Not Enough

Multiple studies have demonstrated that urokinase plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) have clinical utility as breast cancer biomarkers. uPA is an extracellular matrix-degrading protease involved in cancer invasion and metastasis. PAI-1 is thought to enhance angiogenesis and block apoptosis. Although PAI-1 inhibits the activity of uPA, very high levels of these two […]

By |December 20th, 2015|Breast Cancer|0 Comments

What is Triple Negative Breast Cancer and What does it Mean for Treatment?

Breast cancer is a disease that has many different subtypes, each with varying treatments and outcomes. The breast cancer subtypes are differentiated by the type of receptors expressed on the surface of the tumor cells. Knowing the receptor status of tumor cells is important as it helps to determine the most effective treatment.

Triple negative breast […]

By |December 9th, 2015|Breast Cancer|0 Comments

TIMP-1 and HER2 ECD as Biomarkers for Breast Cancer

Researchers are currently investigating tissue inhibitor of metalloproteinases (TIMP) as potential biomarkers in a number of different diseases including cancer, cardiovascular disease, chronic lung disease and diabetes. TIMPs may be especially relevant as cancer biomarkers because they inhibit the activity of matrix metalloproteinases (MMPs), which play a role in tumor invasion and metastasis. Many studies […]

By |December 2nd, 2015|Breast Cancer|0 Comments